Latest News and Press Releases

REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Alvotech (NASDAQ: ALVO) tekur þátt í árlegri heilbrigðisráðstefnu BofA Securities í Las Vegas, Nevada sem haldin verður í dagana 13.–15. maí nk. Fulltrúar félagsins funda með fjárfestum og sitja fyrir...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA...

Not to be released, published, distributed or circulated in the United States or any other jurisdiction in which it would be unlawful to do so. This press release is for information purposes only and...

Heildartekjur á fyrsta fjórðungi ársins voru 132,8 milljónir dollara, samanborið við 36,9 milljónir á sama fjórðungi í fyrra, sem er 260% aukning Sölutekjur á fyrsta fjórðungi ársins voru 109,9...

Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increase Product Revenues in the first in the first...

Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% increaseProduct Revenues in the first in the first...

Alvotech (NASDAQ: ALVO) áætlar að mögulegir tollar á innflutning lyfja til Bandaríkjanna hefðu hverfandi áhrif á tekjur félagsins af sölu lyfja á árinu. Vöruinnflutningur frá Íslandi fellur undir...

Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the...

REYKJAVIK, Iceland, May 07, 2025 (GLOBE NEWSWIRE) --  Alvotech (NASDAQ: ALVO) (the “Company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for...